Related Experiment Video
Updated: Jun 6, 2025

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Published on: November 19, 2019
Depletion of Adipose Stroma-Like Cancer-Associated Fibroblasts Potentiates Pancreatic Cancer Immunotherapy
Joseph Rupert1, Alexes Daquinag1, Yongmei Yu1
1Center for Metabolic and Degenerative Diseases, The Brown Foundation Institute of Molecular Medicine for the Prevention of Disease, McGovern Medical School, Houston, Texas.
Abstract:
Immune checkpoint blockade therapy, transformative in some cancer types, has remained ineffective for patients with pancreatic cancer. The effects of subpopulations of cancer-associated fibroblasts (CAF) on cancer progression and therapy resistance are incompletely understood. In this study, the roles of CAFs expressing platelet-derived growth factor receptor β (Pdgfrb) and of CAFs expressing markers of adipose stromal cells (ASC) were analyzed in mice with pancreatic ductal adenocarcinoma. Ablation of Pdgfrb+ cells resulted in suppression of primary pancreatic tumor growth, reduction of extracellular matrix deposition, and increased cancer cell metastasis to the liver. A peptide D-CAN, which induces apoptosis in ASC-like CAFs, also reduced pancreatic tumor growth and extracellular matrix deposition while promoting metastases. Single-cell RNA sequencing demonstrated that depletion of either Pdgfrb+ or ASC-like CAFs decreased frequencies of tumor endothelial cells and viable cancer cells. However, whereas depletion of Pdgfrb+ CAFs led to stronger induction of cancer cell aggressiveness markers, depletion of ASC-like CAFs had an opposite effect on remaining CAFs. Depletion of ASC-like CAFs using D-CAN also led to higher infiltration of cytotoxic T-lymphocytes and B-lymphocytes. Administration of anti-PDL1 antibody (aPDL1), which inhibits the immune checkpoint, had a stronger suppressive effect on tumor growth when combined with D-CAN in both female and male mice. Liver metastases were also reduced by the D-CAN/aPDL1 combination more effectively than by aPDL1 alone in female mice. We conclude that improved approaches to target ASC-like CAFs may be effective in combination with immunotherapy.
Significance:
This study shows that populations of CAFs have distinct effects on pancreatic cancer progression and shows that depletion of CAFs expressing adipose markers potentiates tumor/metastasis suppression effects of immune checkpoint blockade.
Insights
Targeting adipose stromal cell-like cancer-associated fibroblasts (CAFs) with D-CAN peptide enhances immune checkpoint blockade therapy effectiveness in pancreatic cancer models. This approach may improve treatment outcomes for patients resistant to current immunotherapies.
Area of Science:
- Oncology
- Immunology
- Cancer Biology
Background:
- Immune checkpoint blockade (ICB) therapy is ineffective in pancreatic cancer.
- Cancer-associated fibroblasts (CAFs) influence tumor progression and therapy resistance.
- Subpopulations of CAFs, including Pdgfrb+ CAFs and adipose stromal cell (ASC)-like CAFs, have distinct roles.
Purpose of the Study:
- To investigate the roles of Pdgfrb+ CAFs and ASC-like CAFs in pancreatic ductal adenocarcinoma progression and therapy resistance.
- To evaluate the therapeutic potential of targeting ASC-like CAFs, alone and in combination with ICB.
Main Methods:
- Analysis of CAFs in mouse models of pancreatic ductal adenocarcinoma.
- Ablation of Pdgfrb+ cells and induction of apoptosis in ASC-like CAFs using peptide D-CAN.
- Single-cell RNA sequencing to assess cellular composition and markers.
- Combination therapy with D-CAN and anti-PDL1 (aPDL1) antibody.
Main Results:
- Ablation of Pdgfrb+ CAFs suppressed tumor growth but increased liver metastasis.
- D-CAN treatment reduced tumor growth and extracellular matrix deposition but promoted metastasis.
- Depletion of either CAF subpopulation altered tumor microenvironment, affecting endothelial cells and cancer cells.
- Depletion of ASC-like CAFs increased cytotoxic T-lymphocyte and B-lymphocyte infiltration.
- Combination of D-CAN and aPDL1 showed enhanced tumor suppression and reduced liver metastasis compared to aPDL1 alone.
Conclusions:
- Targeting ASC-like CAFs with D-CAN can potentiate the anti-tumor effects of immune checkpoint blockade in pancreatic cancer.
- Distinct CAF subpopulations have opposing effects on tumor progression and metastasis.
- Combination therapy targeting ASC-like CAFs and immune checkpoints offers a promising strategy for pancreatic cancer treatment.
Related Concept Videos
The Tumor Microenvironment
Tumor Immunotherapy

